ROCKstar Phase II Trial of Daily or Twice-Daily Belumosudil (KD025) in Previously Treated Patients With Chronic GVHD

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In patients with cGVHD after alloSCT and 2-5 prior lines of systemic therapy, belumosudil was well tolerated with response rates > 70% and a median DoR of 50 weeks.
Format: Microsoft PowerPoint (.ppt)
File Size: 289 KB
Released: December 14, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Dr Jeff Sharman provides expert insight into the optimal treatment combinations in the management of CLL/SLL, from Clinical Care Options (CCO)

Jeff Sharman, MD Released: November 22, 2022

Video featuring an expert discussion of BTK inhibitors for CLL and MCL, from Clinical Care Options (CCO)

Matthew S. Davids, MD, MMSc Anthony Mato, MD, MSCE Jeff Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: November 22, 2022 Expired: November 21, 2023

Expert slides on nursing care for patients receiving CAR T-cells, including managing acute and long-term toxicities, from Clinical Care Options (CCO)

person default Kathryn Ciccolini, DNP, AGACNP-BC, OCN Linda Ramsdell, MSN, FNP-BC, OCN Released: November 17, 2022

Expert commentary on data from the SOHO 2022 Annual Meeting on BTK inhibitors for CLL and MCL, from Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings